NCT03945591View on ClinicalTrials.gov

High-Dose Post-Transplant Cyclophosphamide and Bortezomib (CyBor) for the Prevention of Graft-versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)

PHASE2CompletedINTERVENTIONAL
Enrollment

23

Participants

Timeline

Start Date

June 20, 2019

Primary Completion Date

December 29, 2022

Study Completion Date

January 4, 2024

Conditions
GVHD
Interventions
DRUG

Bortezomib

1.3 mg/m2 IV 6 hours after graft infusion and 72 hours thereafter.

DRUG

Cyclophosphamide

50 mg/kg IV over 2 hours on Day +3 and +4

Trial Locations (1)

10016

New York University School of Medicine, New York

All Listed Sponsors
lead

NYU Langone Health

OTHER

NCT03945591 - High-Dose Post-Transplant Cyclophosphamide and Bortezomib (CyBor) for the Prevention of Graft-versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) | Biotech Hunter | Biotech Hunter